OR

Browse By

Histone deacetylase inhibitors can inhibit tumour growth via induction of an anti-tumour immune response (2008–2009)

Abstract:
Conventional anti-cancer therapies have many debilitating side effects, including suppressing the immune system which has demonstrated anti-cancer activity. New chemotherapeutic drugs are more targeted with fewer side effects. Consequently, it is possible to combine the benefits of chemotherapy and immunotherapy. If successful, we will determine how anti-cancer treatment with these drugs can be optimised to improve curative outcomes.
Grant type:
Cancer Council Queensland
Researchers:

  • Professor Brian Gabrielli

    Honorary Professor
    Mater Research Institute-UQ
    Faculty of Medicine
    Honorary Professor
    Mater Research Institute-UQ
    Faculty of Medicine

  • Associate Professor Graham Leggatt

    Associate Professor in Immunology
    Frazer Institute
    Faculty of Medicine
    Associate Professor in Immunology
    Frazer Institute
    Faculty of Medicine
    Director (Research Training)
    Faculty of Medicine
    Director (Research Training)
    Research Strategy and Support (Medicine)
    Faculty of Medicine
    Affiliate Associate Professor of Sc
    School of Biomedical Sciences
    Faculty of Medicine
Funded by:
Cancer Council Queensland